Zenas BioPharma (ZBIO) Net Margin (2023 - 2026)

Zenas BioPharma (ZBIO) posted quarterly Net Margin of 335.73% for Q1 2025, up 67.83% quarter-over-quarter from 1043.5% in Q4 2024.

Zenas BioPharma (ZBIO) Net Margin (2023 - 2026) Analysis & Trends

Zenas BioPharma's Net Margin history runs 3 years deep, the most recent figure standing at 335.73% for Q1 2025.

In Q1 2025, Net Margin changed N/A year-over-year to 335.73%; the TTM figure through Dec 2025 stood at 3884.3% (down 75314.0% YoY), while the FY2025 annual figure was 3884.3%, down 74454.0% from the prior year.
Net Margin for Q1 2025 stood at 335.73%, up from 1043.5% in the prior quarter.
The five-year high for Net Margin was 71.25% in Q3 2023, with the low at 1043.5% in Q4 2024.
The 3-year median for Net Margin is 335.73% (2025), against an average of 435.99%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	30.33%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.90%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	30.98%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	12.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-3.12%
10	Zenas BioPharma	1.87 Bn	748.44 Mn	-	-11,145.60%

Download Data